Blood based monitoring for all solid organ tumours
cancertrack is a minimally invasive, blood-based test that analyses ctDNA, CTCs and/or exosomes in the course of cancer. Recurrences or disease progression can thus be detected as early as possible and therapy can be adjusted.
cancertrack can be used to monitor the disease / recurrence or changes in the tumour characteristics, as often as necessary.
Features of cancertrack
- Multi-coordinate and multidimensional probes to track down DNA / RNA released by cancer cells in the patient’s blood
- Unique, unprecedented capability to detect cancerous activity
- Enables real-time rapid response to the dynamic molecular proﬁle of a patient’s cancer
- Safe, simple and cost-effective
- Rapid lab result
- Tests all active disease sites
- Limits of detection is 0.1% Mutant Allele Frequency
cancertrack is suitable for
... every person who has been diagnosed with cancer, as a supplement to conventional biopsy for a more robust molecular diagnosis and baseline measurement of cell-free tumour DNA and CTC values before initiation of therapy.
... every patient who is under treatment for cancer.
... every patient who is in remission / a cancer survivor and needs monitoring.
Optimally, the treatment is always one step ahead of the cancer. cancertrack ensures real-time monitoring to detect genetic changes in the tumor at an early stage. Clinically relevant mutations can thereby be monitored, or medication can be aligned with the results.
What can cancertrack reveal?
CTC & ctDNA
Indication of cancerous activity in the body
CTC & Exosomes
Indication of molecular dynamics in real-time
CTC & ctDNA
Early relapse detection
Molecular signs of drug resistance
Indication of Loss of Heterozygosity (LOH) + Copy Number Variation (CNV)
cancertrack has been validated clinically on several hundred samples and the process validation meets and exceeds the claimed sensitivity and speciﬁcity. cancertrack has a combined sensitivity of 99.28% and a positive predictive value of 100%.
The molecular evolution of the tumour including tumour size and molecular diversity, is a continuous process, which is progressing at enormous speed. There are many strategies and drugs available today that can intercept cancerous growth effectively. Thus, earlier detection of the primary / recurrence / drug resistance is essential for an oncologist to make informed decisions.
cancertrack should ideally be performed at every important milestone during cancer disease and especially when the tumour has disappeared from conventional imaging / patient is under follow-up for recurrence monitoring.
While cancertrack is extremely robust and multidimensional, like every molecular diagnostic technique, constraints naturally arising due to biological function in an individual patient may impact performance. However, such events are usually averaged out in sequential testing.